The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma

Yoh, K.; Lee, Ho Sup; Park, Lee Chun; Lee, Eun Mi; Shin, Seong Hoon; Park, Dae Jin; Ye, Byeong Jin; Kim, Yang Soo

doi:10.1016/j.clml.2013.09.008

Cited by 23 publications

(19 citation statements)

References 34 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased levels of circulating ferritin, the body's primary iron storage protein, have been reported in a wide range of malignancies [13–16, 26–28]; moreover, increased ferritin levels are often related to decreased survival time and more aggressive disease progression [29]. For example, increased serum ferritin levels have been associated with the incidence, development, and metastasis of primary lung cancer [14].…”

Section: Discussionmentioning

confidence: 99%

“…For example, increased serum ferritin levels have been associated with the incidence, development, and metastasis of primary lung cancer [14]. Moreover, serum ferritin level has also been shown to be a reliable prognostic indicator in hepatocellular carcinoma [13] and other malignancies [12, 16, 22, 23, 30, 31]. Furthermore, serum ferritin measurements have been combined with more traditional cancer biomarkers such as CEA (carcinoembryonic antigen) and AFP (alpha-fetoprotein) for use as a diagnostic and/or prognostic marker in several types of cancer [14, 32].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, an increasing number of studies have demonstrated that circulating ferritin is elevated in patients with a variety of malignant cancer types [12–18] and is associated with cancer risk [19–21]. In addition, recent studies have suggested the potential clinical value of circulating ferritin in several malignancies, including hepatocellular carcinoma [13], lung carcinoma [14], non-Hodgkin lymphoma [16], pancreatic cancer [22], and colorectal cancer [23]. These studies support the notion that ferritin may serve as a suitable biomarker in the diagnosis and prognosis of various cancer types.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer

Wang

Zeng

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Ferritin is highly expressed in many cancer types. Although a few studies have reported an association between high serum ferritin levels and an increased risk of prostate cancer, the results are inconsistent. Therefore, we performed a large case-control study consisting of 2002 prostate cancer patients and 951 control patients with benign prostatic hyperplasia (BPH). We found that high ferritin levels were positively associated with increased serum prostate-specific antigen (PSA) levels and prostate cancer risk; each 100 ng/ml increase in serum ferritin increased the odds ratio (OR) by 1.20 (95% CI: 1.13−1.36). In the prostate cancer group, increased serum ferritin levels were significantly correlated with higher Gleason scores (p < 0.001). Notably, serum PSA values had even higher predictive accuracy among prostate cancer patients with serum ferritin levels > 400 ng/ml (Gleason score + total PSA correlation: r = 0.38; Gleason score + free PSA correlation: r = 0.49). Moreover, using immunohistochemistry, we found that prostate tissue ferritin levels were significantly higher (p < 0.001) in prostate cancer patients (n = 129) compared to BPH controls (n = 31). Prostate tissue ferritin levels were also highly correlated with serum ferritin when patients were classified by cancer severity (r = 0.81). Importantly, we found no correlation between serum ferritin levels and the inflammation marker C-reactive protein (CRP) in prostate cancer patients. In conclusion, serum ferritin is significantly associated with prostate cancer and may serve as a non-invasive biomarker to complement the PSA test in the diagnosis and prognostic evaluation of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer

Wang

Zeng

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Besides, Serum Ferritin concentration closely follows the activity of the malignant lymphomas [20]. Other research work [21] has shown that levels of Serum Ferritin higher than 500 ng/mL is an important marker for predicting poor survival outcomes for non-Hodgkin Lymphoma. Nevertheless, and up to our knowledge, Serum Ferritin levels have not been yet related to the treatment response of HL patients.…”

Section: Discussionmentioning

confidence: 99%

On the prediction of Hodgkin lymphoma treatment response

et al. 2015

View full text Add to dashboard Cite

-Martínez, jlfm@uniovi.es, 0034 985 103 199. AbstractPurpose: The cure rate in Hodgkin Lymphoma is high, but the response along the treatment is still unpredictable and is highly variable among patients. Detecting those patients that do not respond to the treatment at early stages could bring improvements in their treatment. This research tries to identify the main biological prognostic variables currently gathered at diagnosis, and designing a simple machine learning methodology to help physicians improving the treatment response assessment. Methods: We carried out a retrospective analysis of the response to treatment for a cohort of 263 Caucasians who were diagnosed with Hodgkin Lymphoma in Asturias (Spain). For that purpose, we used a list of 35 clinical and biological variables that are currently measured at diagnosis, before any treatment begins. To establish the list of most discriminatory prognostic variables for the treatment response we designed a machine learning approach based on two different feature selection methods (Fisher's ratio and Maximum Percentile Distance) and recursive feature elimination using a nearest-neighbor classifier (k-NN). The weights of the k-NN classifier are optimized using different terms of the confusion matrix (true and false positive rates) in order to minimize risk in the decisions. Results and conclusions: We found that the optimum strategy to predict treatment response in Hodgkin lymphoma consists in solving two

show abstract

“…In the chemotherapy scheme of lymphoma, a classic chemotherapy method, which is still commonly used, is CHOP therapy, which consists of cyclophosphamide, doxorubicin, vincristine, and prednisone. However, using CHOP therapy, patient's survival have historically been poor, particularly in the case of aggressive NHL (Yoh et al, 2014). Since approved by FDA in 1997, the monoclonal CD20 antibody rituximab combinating with CHOP, called R-CHOP therapy, for the treatment of B-NHL represents one satisfactory example in rapid and widespread use (Harrison et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

FNC, a Novel Nucleoside Analogue, Blocks Invasion of Aggressive Non-Hodgkin Lymphoma Cell Lines Via Inhibition of the Wnt/β-Catenin Signaling Pathway

Zhang

Wang²,

Ding³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Chemotherapy is the primary therapy for malignant lymphoma (ML). However, the clinical outcome is still far from satisfactory. Consequently, an understanding of the mechanism of modulating cancer cell invasion, migration and metastasis is important for the development of more effective chemotherapeutic agents. FNC, 2'-deoxy-2' -β-fluoro -4'-azidocytidine, a novel cytidine analogue, has demonstrated significantly inhibitory effects on proliferation of several non-Hodgkin lymphoma (NHL) cell lines. A previous study indicated that FNC effectively inhibited the growth of Raji and JeKo-1 cells in dose-time dependent effects with IC 50 values of 0.2μM and 0.097μM, respectively. This study was focused on investigating the anti-invasive properties of FNC on NHL cells and its potential mechanisms of action. Cell adhesion and transwell chamber assays were utilized to investigate the anti-invasive effects of FNC on Raji and JeKo-1 cells. Real-time PCR and Western blotting were employed to qualify the expression of β-catenin, the glycogen synthase kinase-3 beta (GSK-3β), E-cadherin vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The results revealed that FNC remarkably inhibited the adhesion, migration and invasion of two human aggressive non-Hodgkin lymphoma cell lines in a dose dependent manner. Furthermore, β-catenin, MMP-2, MMP-9, VEGF mRNA and protein levels were decreased after FNC treatment, while GSK-3β and E-cadherin increased. Our studies thus provide evidence and a rationale that FNC may offer an effective chemotherapeutic agent by regulating the invasion and metastasis of aggressive non-Hodgkin lymphoma via inhibition of the Wnt/β-catenin signaling pathway.

show abstract

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma

Abstract: Elevated levels of serum ferritin of 500 ng/mL or more as well as the use of chemotherapy regimens besides CHOP-like or RCHOP, a high-intermediate/high risk IPI, and a high level of beta2-microglobulin in NHL may be an important marker for predicting poor survival outcomes.

Cited by 23 publications

References 34 publications

Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer

Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer

On the prediction of Hodgkin lymphoma treatment response

FNC, a Novel Nucleoside Analogue, Blocks Invasion of Aggressive Non-Hodgkin Lymphoma Cell Lines Via Inhibition of the Wnt/β-Catenin Signaling Pathway

Contact Info

Product

Resources

About